cbdMD (YCBD) Gross Margin (2016 - 2026)

cbdMD (YCBD) posted Gross Margin of 59.82% for Q4 2025, up 1.69% sequentially from 58.83% in Q3 2025, and down 668.0% YoY from 10.53% in Q4 2024.

cbdMD (YCBD) Gross Margin (2016 - 2026) Analysis & Trends

cbdMD has reported Gross Margin for 10 years, with the latest figure at 59.82% in Q4 2025.

Quarterly Gross Margin fell 668.0% year-over-year to 59.82% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 60.59% (up 37.0% YoY) and the FY2025 annual result came in at 62.37%, up 215.0% from the prior year.
Gross Margin improved to 59.82% in Q4 2025 per YCBD's latest filing, from 58.83% in the prior quarter.
Over five years, Gross Margin peaked at 72.91% in Q3 2023 and troughed at 49.11% in Q3 2024.
A 5-year average of 61.44% and a median of 62.58% in 2023 frame the typical range for Gross Margin.
The sharpest annual moves came in 2023 and 2024: Gross Margin jumped 2104 bps in 2023, then sank 2380 bps in 2024.
Over 5 years, Gross Margin stood at 50.66% in 2021, then advanced by 13 bps to 57.17% in 2022, then rose by 16 bps to 66.18% in 2023, then rose by 0 bps to 66.5% in 2024, then dropped by 10 bps to 59.82% in 2025.
According to Business Quant data, Gross Margin over the past three periods registered 59.82%, 58.83%, and 61.45% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	-
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	51.98%
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	42.63%
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	66.66%
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	87.30%
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	38.77%
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	97.58%
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	58.33%
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	cbdMD	5.41 Mn	3.29 Mn	3.04 Mn	54.69%

Download Data